What Does Pro Medicus’s (ASX:PME) Latest Annual Report Mean for Investors?

Sonal Goyal

20 October 2026 04:52 PM AEDT

What Does Pro Medicus’s (ASX:PME) Latest Annual Report Mean for Investors?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key highlights

Pro Medicus said FY26 was its second-biggest year for new contracts, after FY25, in an interview dated 18 August 2026.
Currency movements reduced Revenue by just under $12 million and NPAT by $9.8 million.
The company said it achieved NPAT growth of more than 32% on a constant currency basis.

Pro Medicus Limited (ASX:PME) published an interview with its chief executive on 18 August 2026 discussing its full-year results. The document provided for this article is that interview, rather than a results statement, so figures are limited to those given in the discussion.

About Pro Medicus

Pro Medicus develops and sells the Visage medical imaging platform, which is used by radiologists and healthcare organisations, mainly in the United States. The company says its platform is used by about 11% of the US market, including 11 of the top 20 healthcare institutions, and it has been adding modules such as cardiology.

Contracts, renewals and implementations

The company said FY26 was its second-biggest year for new contracts, after FY25, when it won its largest contract to date. It completed six major renewals and had its busiest year for implementations, many of which came late in the second half. It said those implementations did not contribute materially to FY26 revenue but are expected to provide a step-up in transaction revenue in FY27, when they contribute a full 12 months.

The company also referred to a 100% renewal rate and said customers are increasingly choosing more than one module, which lifts total contract value per client.

Currency effects and profit

The company said the higher Australian dollar affected translated revenue, reducing revenue by just under $12 million and NPAT by $9.8 million. It said it met its goal of increasing NPAT by more than 32% on a constant currency basis, and that it regards constant currency results as a better reflection of performance.

AI, investments and capital

The company said its platform positions it as the radiologist’s desktop and a gateway for image-based AI, and that it expects to layer algorithms, whether its own, co-developed or from third parties. It referred to investments of $10 million in 4D Medical in July 2025 and a further $10 million planned in Echo IQ, cash and financial Assets of over $250 million, a 25% increase in the full-year Dividend payout and a share buy-back.

Risks to consider

Revenue from new contracts depends on implementation timing, and the company said most FY26 implementations came late in the second half. Currency movements affected FY26 results and may continue to do so, given its US revenue base.

The platform is concentrated in the US healthcare market, where contract renewals and procurement decisions are material. Statements about AI benefits are forward looking, and the interview does not provide audited figures.

Catalysts to watch

Items to watch include revenue from the FY26 implementations over a full 12 months in FY27, further renewals, new cardiology and other module sales, investments in 4D Medical and Echo IQ, and currency effects.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.